The content on this site is intended for healthcare professionals only
Advice to young oncologists
Advances in advanced renal cell carcinoma from ESMO 2012: Part 1
Advances in advanced renal cell carcinoma from ESMO 2012: Part 3
Advances in advanced renal cell carcinoma from ESMO 2012: Part 2
Advances in advanced metastatic renal cell carcinoma from ESMO 2012
Treating platinum resistant ovarian cancer
Developing technologies for personalised treatment
Nab-paclitaxel and gemcitabine combating pancreatic cancer
Chemotherapy and radiotherapy in advanced local non-small cell lung cancer
Hepatic chemosaturation therapy
Advances in soft tissue sarcoma from ESMO 2012
Genes, chromosomes and the treatment of bladder cancer
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)
Surgical challenges to retroperitoneal sarcomas
Treatment approaches for desmoid tumours
Development and expansion of the IFOM-IEO campus
Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype
Clinical trials and drug developments in pancreatic cancer
The Neo ALTO Study, combination therapy of lapatinib and trastuzumab and breast conservation surgery
Histology and non-histology driven therapy for soft tissue sarcomas and the Rare Cancers Europe initiative
MET inhibitors for non-small cell lung cancer
Multidisciplinary benefits to radiotherapy
Pathology and development of ovarian cancer
Putting the theory of personalised medicine into practice
Treatment of ALK+ lung cancer with crizotinib, Profile 1007
The first phase II trial for the management of oesophageal cancer
Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer
Trametinib and dabrafenib combination therapy against metastatic melanoma
New developments in molecular imaging
Personalised cancer medicine and research: Today’s best practice
Treating liver metastases in colorectal cancer
Putting drugs to work against brain metastases in HER2 positive breast cancer: LANDSCAPE study
The Multinational Association of Supportive Care in Cancer (MASCC)
Defining personalised medicine and patient empowerment
Phase I study examining PI 3 kinase inhibitor for various tumours
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer
Too few women being offered breast-conserving treatment?
Personalised medicine: Hype or hope?
Awareness of personalised medicine in cancer patients
BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma
Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF
Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial
